Valuation dashboard for Niagen Bioscience Inc (NAGE) with P/E 15.45, P/B 2.88, EV/EBITDA 9.62 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredi...
Analysis Summary
Niagen Bioscience Inc reported revenue of $129.4M in the most recent fiscal year, growing at a 5-year CAGR of 16.9%.
Trailing-twelve-month margins: gross margin 64.2%, operating margin 6.7%, net margin 12.4%.
At the current price of $3.00, NAGE trades at a P/E of 15.45 and an ROE of 20.50%. Market capitalisation stands at $239M.
Balance sheet quality for NAGE: current ratio of 4.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 15.45 |
| Price / Book | 2.88 |
| EV / EBITDA | 9.62 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.38 |
| vs Current Price | -146.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NAGE | Niagen Bioscience Inc | $239M | 15.45 | 2.88 | 20.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.00 |
| Market Cap | $239M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 20.50% |
| Return on Invested Capital | 8.75% |
| Return on Assets | 15.00% |
| Gross Margin | 64.24% |
| Operating Margin | 6.67% |
| Net Margin | 12.39% |
Related companies: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of NAGE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks